Cash-pay telehealth with clean monthly and annual recurring revenue is a real asset class. Strategic buyers and public platforms have paid large, disclosed prices for digital health companies, often framed against revenue run-rate. Your clinic will not sell at megadeal multiples by default, but the comps prove the category trades, and owners with documented MRR, retention, and compliance are the ones who can negotiate.
Why multiples matter if you own the clinic
If you build a clinic you own from day one, exit is not a slogan. It is the question of what a buyer will pay for your recurring patient base, brand, and operating stack. Buyers underwrite MRR and ARR the way SaaS buyers do: how durable is the revenue, how expensive is retention, and how clean is the compliance story.
Clinic Builder will buy performing clinics. That is a real path. It is not the only path. Public and private M&A in digital health shows that scale, growth, and recurring revenue command serious capital when the books and operations hold up under diligence.
A recent comps: Hims & Hers and Eucalyptus
In early 2026, U.S. telehealth company Hims & Hers announced an agreement to acquire Australian digital health company Eucalyptus for up to about $1.15 billion, with consideration tied to a January 2026 revenue run-rate and strong ARR growth through 2025. Deal commentary around the announcement framed the implied historic revenue multiple in the mid- to high-single-digit range, at the upper end of general digital health benchmarks that often sit roughly in the mid-single digits for broader assets and higher for premium telehealth platforms with growth and embedded workflows.
That deal is not a valuation formula for a clinic with a few hundred patients. It is proof that subscription-style digital health businesses with real run-rate get priced as growth assets, not as one-off lead gen sites. For a longer write-up of the transaction context, see ION Analytics / Mergermarket coverage of the Hims & Hers Eucalyptus acquisition.
The category-defining megadeal: Teladoc and Livongo
Virtual care M&A has priced even higher at the top of the cycle. In 2020, Teladoc agreed to acquire Livongo for roughly $18.5 billion. Contemporary reporting described that purchase price as on the order of about 30 times Livongo's projected 2021 revenue, a peak-era multiple that later cooled with the broader digital health market. Healthcare Dive's coverage of the announcement remains a clear primary secondary source for how the Street debated that valuation at the time: Teladoc-Livongo megadeal analysis.
Peak multiples are not a promise. They are a ceiling that proves institutional capital will pay for recurring virtual care revenue when growth and strategic fit align.
What that means for a clinic you own
Smaller cash-pay clinics do not trade like public-platform megadeals. They do trade on the same underlying logic:
- MRR and ARR quality. Paid, retained patients beat vanity lead counts.
- Retention and refill behavior. Buyers diligence cohort curves, not launch-month screenshots.
- Clean ownership. Entity, processors, ad accounts, brand, and patient relationships that sit in your name from day one.
- Compliance that survives diligence. LegitScript, pharmacy routing, and provider coverage that do not unwind at sale.
That is why we build exit-ready infrastructure into the launch instead of bolting it on later. When Clinic Builder offers to buy a performing clinic, or when you shop it to another operator, you are negotiating from an asset package, not a login list.
How to think about your own exit without over-promising
We will not publish a contractual buyout formula. Markets move. What we will say plainly:
- We will buy clinics that are performing.
- Healthy MRR and ARR multiples exist in telehealth for businesses that can prove retention and compliance.
- Your job as an owner is to keep the books, the patient base, and the operating stack sale-ready from day one.
If you want the build path that produces that asset, start with how the 30-day launch works, then read what makes a telehealth clinic exit-ready.
Disclaimer: This article is educational and does not constitute investment, legal, or financial advice. Cited deal sizes and multiples are drawn from public reporting on third-party transactions and are not forecasts of what any Clinic Builder client clinic will sell for. Individual results vary. Clinic Builder builds and scales turnkey telehealth businesses owned by clients; we do not provide medical care.
